Pharsight

Daytrana patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9668981 NOVEN PHARMS INC Device for transdermal administration of drugs including acrylic based polymers
Oct, 2025

(1 year, 6 months from now)

US8632802 NOVEN PHARMS INC Device for transdermal administration of drugs including acrylic polymers
Oct, 2025

(1 year, 6 months from now)

US9034370 NOVEN PHARMS INC Device for transdermal administration of drugs including acrylic polymers
Oct, 2025

(1 year, 6 months from now)

Daytrana is owned by Noven Pharms Inc.

Daytrana contains Methylphenidate.

Daytrana has a total of 3 drug patents out of which 0 drug patents have expired.

Daytrana was authorised for market use on 06 April, 2006.

Daytrana is available in film, extended release;transdermal dosage forms.

Daytrana can be used as method for transdermally delivering a drug to a user in need thereof.

The generics of Daytrana are possible to be released after 07 October, 2025.

Drugs and Companies using METHYLPHENIDATE ingredient

Market Authorisation Date: 06 April, 2006

Treatment: Method for transdermally delivering a drug to a user in need thereof

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

How can I launch a generic of DAYTRANA before it's drug patent expiration?
More Information on Dosage

DAYTRANA family patents

Family Patents